February 8, 2006 – Pfizer announced it would consider selling its consumer products division, which brought in $4 billion in revenue last year; Adolor was the trading star of the day, climbing 41% on news that its lead drug, Entereg, was effective against post-operative ileus; Oscient Pharma acquired world-wide rights to a Clostridium difficile-associated therapy from Pfizer; Cell Therapeutics received fast-track status for Xyotax, an enhanced version of Taxol; Cytogen has inlicensed Soltamox, an oral liquid hormone therapy, fromSavient; Pharmacopeia received a milestone from Celgene for drug discovery; GTCR Golder Rauner, LLC, a private equity firm, has set up a former head of King Pharmaceuticals with $200 million in cash and a brief to in-license drugs. Today, the Centient Biotech 200™ was off by 10 points at 3874.67, a decline of .25%. More details...
